Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

2.

Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care [Internet].

Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Stave CD, Zehnder JL, Olkin I, McDonald KM, Owens DK, Stafford RS.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 May.

3.

Assessing applicability when comparing medical interventions: AHRQ and the Effective Health Care Program.

Atkins D, Chang SM, Gartlehner G, Buckley DI, Whitlock EP, Berliner E, Matchar D.

J Clin Epidemiol. 2011 Nov;64(11):1198-207. doi: 10.1016/j.jclinepi.2010.11.021. Epub 2011 Apr 3.

PMID:
21463926
4.

Haemostatic drug therapies for acute spontaneous intracerebral haemorrhage.

Al-Shahi Salman R.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD005951. doi: 10.1002/14651858.CD005951.pub3. Review.

PMID:
19821350
5.

Scientific and logistical challenges in designing the CONTROL trial: recombinant factor VIIa in severe trauma patients with refractory bleeding.

Dutton R, Hauser C, Boffard K, Dimsitts J, Bernard G, Holcomb J, Leppäniemi A, Tortella B, Bouillon B; CONTROL Steering Committee.

Clin Trials. 2009 Oct;6(5):467-79. doi: 10.1177/1740774509344102. Epub 2009 Sep 8.

PMID:
19737846
6.

Diagnosis and management of coagulopathy after major trauma.

Brohi K.

Br J Surg. 2009 Sep;96(9):963-4. doi: 10.1002/bjs.6691.

PMID:
19672928
7.

Massive transfusion protocols: the role of aggressive resuscitation versus product ratio in mortality reduction.

Riskin DJ, Tsai TC, Riskin L, Hernandez-Boussard T, Purtill M, Maggio PM, Spain DA, Brundage SI.

J Am Coll Surg. 2009 Aug;209(2):198-205. doi: 10.1016/j.jamcollsurg.2009.04.016. Epub 2009 Jul 9.

PMID:
19632596
8.

High incidence of thromboembolic events in left ventricular assist device patients treated with recombinant activated factor VII.

Bruckner BA, DiBardino DJ, Ning Q, Adeboygeun A, Mahmoud K, Valdes J, Eze J, Allison PM, Cooley DA, Gregoric ID, Frazier OH.

J Heart Lung Transplant. 2009 Aug;28(8):785-90. doi: 10.1016/j.healun.2009.04.028.

PMID:
19632574
9.

AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program.

Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, Chang S, Helfand M.

J Clin Epidemiol. 2010 May;63(5):513-23. doi: 10.1016/j.jclinepi.2009.03.009.

PMID:
19595577
10.

Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery.

Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, Sellke F, Booth F, Schmidt TA.

Circulation. 2009 Jul 7;120(1):21-7. doi: 10.1161/CIRCULATIONAHA.108.834275. Epub 2009 Jun 22.

11.

International resuscitation research, exception from informed consent, and the European Union Directive 2001/20/EC.

Lewis RJ, Duber HC, Biros MH, Cone DC; International Regulatory Status of Emergency Exception to Informed Consent Study Group.

Eur J Emerg Med. 2009 Oct;16(5):234-41. doi: 10.1097/MEJ.0b013e32830fe959.

PMID:
19433982
12.

Effect of recombinant factor VIIa as an adjunctive therapy in damage control for wartime vascular injuries: a case control study.

Fox CJ, Mehta SG, Cox ED, Kragh JF Jr, Salinas J, Holcomb JB.

J Trauma. 2009 Apr;66(4 Suppl):S112-9. doi: 10.1097/TA.0b013e31819ce240.

PMID:
19359954
13.

Transfusion of blood products in trauma: an update.

Fraga GP, Bansal V, Coimbra R.

J Emerg Med. 2010 Aug;39(2):253-60. doi: 10.1016/j.jemermed.2009.02.034. Epub 2009 Apr 3. Review.

PMID:
19345046
14.

Recombinant activated factor VII in the treatment of non-haemophilia patients: physician under-reporting of thromboembolic adverse events.

Hsia CC, Zurawska JH, Tong MZ, Eckert K, McAlister VC, Chin-Yee IH.

Transfus Med. 2009 Feb;19(1):43-9. doi: 10.1111/j.1365-3148.2009.00913.x.

PMID:
19302454
15.

Pediatric off-label use of recombinant factor VIIa.

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Pediatrics. 2009 Mar;123(3):1066-72. doi: 10.1542/peds.2008-1685.

PMID:
19255041
16.

Recombinant factor VIIa plus surgery for intracerebral hemorrhage.

Sutherland CS, Hill MD, Kaufmann AM, Silvaggio JA, Demchuk AM, Sutherland GR.

Can J Neurol Sci. 2008 Nov;35(5):567-72.

PMID:
19235439
17.

Use of recombinant factor VIIa (NovoSeven) in pediatric cardiac surgery.

Niles SD, Burkhart HM, Duffey DA, Buhrman K, Burzynski J, Holt DW.

J Extra Corpor Technol. 2008 Dec;40(4):241-8.

18.

Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma.

Stein DM, Dutton RP, Kramer ME, Scalea TM.

J Trauma. 2009 Jan;66(1):63-72; discussion 73-5. doi: 10.1097/TA.0b013e318191bc8a.

PMID:
19131807
19.

Reconstituted fresh whole blood improves clinical outcomes compared with stored component blood therapy for neonates undergoing cardiopulmonary bypass for cardiac surgery: a randomized controlled trial.

Gruenwald CE, McCrindle BW, Crawford-Lean L, Holtby H, Parshuram C, Massicotte P, Van Arsdell G.

J Thorac Cardiovasc Surg. 2008 Dec;136(6):1442-9. doi: 10.1016/j.jtcvs.2008.08.044.

20.

Risks and predictors of blood transfusion in pediatric patients undergoing open heart operations.

Székely A, Cserép Z, Sápi E, Breuer T, Nagy CA, Vargha P, Hartyánszky I, Szatmári A, Treszl A.

Ann Thorac Surg. 2009 Jan;87(1):187-97. doi: 10.1016/j.athoracsur.2008.09.079.

PMID:
19101294

Supplemental Content

Support Center